Canadian biotech Medicago building $200M vaccine plant

Medicago's Research Triangle Park, NC, facility--Courtesy of Medicago

Medicago is building a $200 million manufacturing facility in Quebec City, where it will use plant technology to produce vaccines against Ebola and other viruses. The company is working with tobacco plants to make large quantities of vaccines. It has made flu vaccines for H1N1 and H7N9 in less than three weeks--much more quickly than making them using the traditional egg-based method. Medicago opened a facility in Research Triangle Park, NC, which can manufacture 10 million vaccine doses per month. More from FiercePharmaManufacturing

Suggested Articles

Merck has a big target in mind for its pneumococcal vaccine V114: Prevnar 13, the world's best-selling shot—and its phase 3 program shows it.

A Lancet Infectious Diseases study shows antibody response persists for two years or more after a single shot of Merck’s rVSV-ZEBOV vaccine.

Behind the under-pressure blockbuster Prevnar 13 are several pipeline vaccines Pfizer hopes will propel future growth.